JPWO2019179424A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019179424A5 JPWO2019179424A5 JP2020550641A JP2020550641A JPWO2019179424A5 JP WO2019179424 A5 JPWO2019179424 A5 JP WO2019179424A5 JP 2020550641 A JP2020550641 A JP 2020550641A JP 2020550641 A JP2020550641 A JP 2020550641A JP WO2019179424 A5 JPWO2019179424 A5 JP WO2019179424A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- glp
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 54
- 102100039997 Gastric inhibitory polypeptide receptor Human genes 0.000 claims description 25
- 101000886866 Homo sapiens Gastric inhibitory polypeptide receptor Proteins 0.000 claims description 25
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 45
- 102000037865 fusion proteins Human genes 0.000 claims 28
- 108020001507 fusion proteins Proteins 0.000 claims 28
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 27
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 210000004899 c-terminal region Anatomy 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 108091026890 Coding region Proteins 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 101100228914 Homo sapiens GIPR gene Proteins 0.000 claims 1
- 101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 101100228916 Mus musculus Gipr gene Proteins 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 102000050325 human granulocyte inhibitory Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810231468.XA CN110305211A (zh) | 2018-03-20 | 2018-03-20 | Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 |
| CN201810231468.X | 2018-03-20 | ||
| PCT/CN2019/078671 WO2019179424A1 (zh) | 2018-03-20 | 2019-03-19 | Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021518132A JP2021518132A (ja) | 2021-08-02 |
| JPWO2019179424A5 true JPWO2019179424A5 (https=) | 2022-04-18 |
| JP2021518132A5 JP2021518132A5 (https=) | 2022-04-18 |
| JP7313372B2 JP7313372B2 (ja) | 2023-07-24 |
Family
ID=67986692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020550641A Active JP7313372B2 (ja) | 2018-03-20 | 2019-03-19 | Gipr抗体及びglp-1とのその融合タンパク質、並びにその医薬組成物及び用途 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11780916B2 (https=) |
| EP (1) | EP3808771A4 (https=) |
| JP (1) | JP7313372B2 (https=) |
| KR (1) | KR20200133365A (https=) |
| CN (3) | CN117003874A (https=) |
| AU (1) | AU2019236822B2 (https=) |
| BR (1) | BR112020019052A2 (https=) |
| CA (1) | CA3094286A1 (https=) |
| TW (1) | TWI832847B (https=) |
| WO (1) | WO2019179424A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112521501A (zh) * | 2019-09-18 | 2021-03-19 | 鸿运华宁(杭州)生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 |
| EP4352104A4 (en) * | 2021-06-09 | 2025-06-04 | Swiftnovo Therapeutics Inc. | Therapeutics and methods for treating or ameliorating metabolic disorders |
| JP2025531814A (ja) * | 2022-09-08 | 2025-09-25 | ジーマックス バイオファーム エルエルシー | Gipr抗体、fgf21との融合タンパク質、その医薬組成物及びその使用 |
| EP4613768A1 (en) * | 2022-11-02 | 2025-09-10 | Suzhou Alphamab Co., Ltd | Gipr binding protein and use thereof |
| WO2025237353A1 (zh) * | 2024-05-15 | 2025-11-20 | 信立泰(成都)生物技术有限公司 | 一种抗gipr抗体或其抗原结合片段及用途 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| ATE240394T1 (de) | 1992-10-23 | 2003-05-15 | Immunex Corp | Methoden zur herstellung löslicher, oligomerer proteine |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
| US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| SE9802080D0 (sv) | 1998-06-11 | 1998-06-11 | Hellstroem | Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein |
| AU5027299A (en) | 1998-07-31 | 2000-02-28 | Novo Nordisk A/S | Use of glp-1 and analogues for preventing type ii diabetes |
| US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
| MY155270A (en) | 1998-09-24 | 2015-09-30 | Lilly Co Eli | Use of glp-1 or analogs in treatment of stroke |
| GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
| TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
| EP2411412B1 (en) * | 2009-03-24 | 2015-05-27 | Teva Biopharmaceuticals USA, Inc. | Humanized antibodies against light and uses thereof |
| CN104371019B (zh) * | 2013-08-13 | 2019-09-10 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
| EP3152235B1 (en) | 2014-05-29 | 2021-08-25 | MacroGenics, Inc. | Tri-specific binding molecules and methods of use thereof |
| AR104250A1 (es) | 2015-04-16 | 2017-07-05 | Eisai R&D Man Co Ltd | Anticuerpo anti-notch4 humano |
| KR102844773B1 (ko) * | 2015-12-23 | 2025-08-13 | 암젠 인크 | 위 억제 펩티드 수용체 (gipr)에 대한 결합 단백질을 glp-1 효능제와 조합하여 사용하여 대사 장애를 치료하거나 개선시키는 방법 |
| MX2019015544A (es) * | 2017-06-21 | 2020-07-28 | Amgen Inc | Metodo para tratar o mejorar trastornos metabolicos con proteinas de fusion de agonistas del receptor de glp-1/proteinas de union antagonistas para el receptor peptidico inhibidor gastrico (gipr). |
-
2018
- 2018-03-20 CN CN202310867018.0A patent/CN117003874A/zh active Pending
- 2018-03-20 CN CN202310866325.7A patent/CN117126279A/zh active Pending
- 2018-03-20 CN CN201810231468.XA patent/CN110305211A/zh active Pending
-
2019
- 2019-03-19 AU AU2019236822A patent/AU2019236822B2/en active Active
- 2019-03-19 US US16/982,443 patent/US11780916B2/en active Active
- 2019-03-19 BR BR112020019052-7A patent/BR112020019052A2/pt unknown
- 2019-03-19 EP EP19771776.2A patent/EP3808771A4/en active Pending
- 2019-03-19 KR KR1020207029941A patent/KR20200133365A/ko active Pending
- 2019-03-19 TW TW108109318A patent/TWI832847B/zh active
- 2019-03-19 WO PCT/CN2019/078671 patent/WO2019179424A1/zh not_active Ceased
- 2019-03-19 JP JP2020550641A patent/JP7313372B2/ja active Active
- 2019-03-19 CA CA3094286A patent/CA3094286A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107206077B (zh) | 靶向g-蛋白偶联受体的抗体和使用方法 | |
| CN109071654B (zh) | 靶向Fc受体样5的抗体及使用方法 | |
| JP6669722B2 (ja) | Cd3結合ドメイン | |
| RU2016108703A (ru) | Антитело, специфически связывающееся с glp-1r, и его слитый с glp-1 белок | |
| JP2020508655A5 (https=) | ||
| JP2019520797A5 (https=) | ||
| JP2021518132A5 (https=) | ||
| JP2020536532A5 (https=) | ||
| JP2018522888A5 (https=) | ||
| JP2005518789A5 (https=) | ||
| JP2013515508A5 (https=) | ||
| JP2020524661A5 (https=) | ||
| CN114786720B (zh) | TriAx抗体的组合物及其制备和使用方法 | |
| JPWO2022111425A5 (https=) | ||
| JP2021518748A5 (https=) | ||
| JPWO2019175368A5 (https=) | ||
| JPWO2019179424A5 (https=) | ||
| JPWO2021052349A5 (https=) | ||
| JP2026500703A (ja) | 融合タンパク質 | |
| JP2021526833A5 (https=) | ||
| JPWO2022150788A5 (https=) | ||
| JPWO2019165326A5 (https=) | ||
| JPWO2022212470A5 (https=) | ||
| JPWO2019238093A5 (https=) | ||
| RU2020130794A (ru) | Антитело к gipr и его слитый с glp-1 белок, а также фармацевтическая композиция на его основе и его применение |